The tissue distribution kinetics of i.v. Cyclosporine A (CyA) was investigated extensively in rats. The concentration-to-time data of 11 organs were analyzed separately using local physiologi-cally based pharmacokinetic models, involving nonlinear plas-ma-to-blood cell distribution, membrane-permeability-limited plasma-to-tissue distribution and either linear or nonlinear tis-sue binding. Two global physiologically based pharmacokinetic models were then evaluated, each comprising arterial and ve-nous pools together with the 11 organs, adopting either of the two local models. Both global models successfully described the blood and tissue distribution kinetics of CyA. In nonlinear model, the estimated dissociation constants (Kd) for the intra...
The pharmacokinetic behavior of cyclosporine A (CyA), known as a potential immunosuppressive agent t...
Therapeutic drug monitoring is used to individualize cyclosporine A (CsA) dosing after transplantati...
Aim. To develop a population pharmacokinetic model for Uruguayan patients under treatment with cyclo...
PURPOSE. To develop an isolated perfused rat liver model to study the hepatic disposition of cyclosp...
Several pharmacokinetic parameters have been used to quantitatively describe distributional processe...
ABSTRACT Background: Cyclosporine A (CsA) has since its introduction in the 1980’s played a substan...
International audienceIn vitro experiments have a high potential to improve current chemical safety ...
Components of whole blood and plasma are highly altered during the presentation of nephrotic syndrom...
Background Ciclosporin A (CsA) is an important part of the immunosuppressive regimen in the treatmen...
We present a sub-compartmentalized model of drug distribution in tissue that extends existing approa...
Cyclosporine A, a potent calcineurin inhibitor, has been widely used in organ transplantation and in...
Cyclosporin is an immunosuppressive agent with a narrow therapeutic index. The total concentration o...
In our companion paper, we described the theoretical basis for tissue lumping in whole-body physiolo...
A model for predicting the magnitude of error ( % Err) in measuring tissue concentrations of a compo...
The distribution kinetics of adriamycin in the rat were analyzed by using a multicompartment mathema...
The pharmacokinetic behavior of cyclosporine A (CyA), known as a potential immunosuppressive agent t...
Therapeutic drug monitoring is used to individualize cyclosporine A (CsA) dosing after transplantati...
Aim. To develop a population pharmacokinetic model for Uruguayan patients under treatment with cyclo...
PURPOSE. To develop an isolated perfused rat liver model to study the hepatic disposition of cyclosp...
Several pharmacokinetic parameters have been used to quantitatively describe distributional processe...
ABSTRACT Background: Cyclosporine A (CsA) has since its introduction in the 1980’s played a substan...
International audienceIn vitro experiments have a high potential to improve current chemical safety ...
Components of whole blood and plasma are highly altered during the presentation of nephrotic syndrom...
Background Ciclosporin A (CsA) is an important part of the immunosuppressive regimen in the treatmen...
We present a sub-compartmentalized model of drug distribution in tissue that extends existing approa...
Cyclosporine A, a potent calcineurin inhibitor, has been widely used in organ transplantation and in...
Cyclosporin is an immunosuppressive agent with a narrow therapeutic index. The total concentration o...
In our companion paper, we described the theoretical basis for tissue lumping in whole-body physiolo...
A model for predicting the magnitude of error ( % Err) in measuring tissue concentrations of a compo...
The distribution kinetics of adriamycin in the rat were analyzed by using a multicompartment mathema...
The pharmacokinetic behavior of cyclosporine A (CyA), known as a potential immunosuppressive agent t...
Therapeutic drug monitoring is used to individualize cyclosporine A (CsA) dosing after transplantati...
Aim. To develop a population pharmacokinetic model for Uruguayan patients under treatment with cyclo...